Evidence map›Paper›PMID 40893225›Full record

ArticleACS omega2025

Crystallographic and Electroanalytical Analyses of Fexinidazole and Its Major Metabolites.

Abdrrahman S Surur, Siva S M Bandaru, Christian Fischer, Van T D Nguyen, Andreas Link, Patrick J Bednarski, Carola Schulzke

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ACS omega, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Abdrrahman S SururDepartment of Medicinal and Pharmaceutical Chemistry, Institute of Pharmacy, University of Greifswald, Greifswald 17489, Germany.ORCID https://orcid.org/0000-0002-4028-068X
Siva S M BandaruDepartment of Bioinorganic Chemistry, Institute of Biochemistry, University of Greifswald, Greifswald 17489, Germany.ORCID https://orcid.org/0000-0003-4294-8521
Christian FischerDepartment of Bioinorganic Chemistry, Institute of Biochemistry, University of Greifswald, Greifswald 17489, Germany.ORCID https://orcid.org/0000-0002-2966-3866
Van T D NguyenDepartment of Medicinal and Pharmaceutical Chemistry, Institute of Pharmacy, University of Greifswald, Greifswald 17489, Germany.
Andreas LinkDepartment of Medicinal and Pharmaceutical Chemistry, Institute of Pharmacy, University of Greifswald, Greifswald 17489, Germany.ORCID https://orcid.org/0000-0003-1262-6636
Patrick J BednarskiDepartment of Medicinal and Pharmaceutical Chemistry, Institute of Pharmacy, University of Greifswald, Greifswald 17489, Germany.ORCID https://orcid.org/0000-0002-9589-8241
Carola SchulzkeDepartment of Bioinorganic Chemistry, Institute of Biochemistry, University of Greifswald, Greifswald 17489, Germany.ORCID https://orcid.org/0000-0002-7530-539X

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Fexinidazole, a drug active against trypanosomiasis and leishmaniasis, is a rare example of a nitroaromatic compound approved under the contemporary drug discovery framework. In an earlier study, we showed that the nitro group is absolutely required for antileishmanial activity. The current study employed X-ray crystallography to unveil the structural intricacies of fexinidazole and its principal metabolites, as well as electroanalytical analyses to characterize the reduction properties of the aromatic nitro group. Fexinidazole showcases a predominantly planar geometry with two distinct conformers. While most metrical parameters were conserved between fexinidazole and its metabolites, differences in the methyl ether bridge and

Identifiers

PMID40893225
PMCPMC12392169

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.